178 related articles for article (PubMed ID: 36473617)
1. Aidi injection enhances the anti-tumor impact of doxorubicin in H22 tumor-containing mice.
Lu Y; Zhang S; Zhu X; Wang K; He Y; Liu C; Sun J; Pan J; Zheng L; Liu W; Li Y; Huang Y; Liu T
J Ethnopharmacol; 2023 Mar; 303():115968. PubMed ID: 36473617
[TBL] [Abstract][Full Text] [Related]
2. Cell metabolomics study on synergistic anti-hepatocellular carcinoma effect of Aidi injection combined with doxorubicin.
Wang Y; Zhu X; Wang K; Cai Y; Liu C; Pan J; Sun J; Liu T; Huang Y; Li Y; Lu Y
Biomed Chromatogr; 2022 Oct; 36(10):e5451. PubMed ID: 35848595
[TBL] [Abstract][Full Text] [Related]
3. Synergistic breast cancer suppression efficacy of doxorubicin by combination with glycyrrhetinic acid as an angiogenesis inhibitor.
Shi J; Li J; Li J; Li R; Wu X; Gao F; Zou L; Mak WWS; Fu C; Zhang J; Leung GP
Phytomedicine; 2021 Jan; 81():153408. PubMed ID: 33234363
[TBL] [Abstract][Full Text] [Related]
4. Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence.
Zhang F; Jia Y; Zheng X; Shao D; Zhao Y; Wang Z; Dawulieti J; Liu W; Sun M; Sun W; Pan Y; Cui L; Wang Y; He K; Zhang M; Li J; Dong WF; Chen L
Acta Biomater; 2019 Dec; 100():352-364. PubMed ID: 31563690
[TBL] [Abstract][Full Text] [Related]
5. Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting β-catenin-mediated angiogenesis.
Shi L; Yang F; Luo F; Liu Y; Zhang F; Zou M; Liu Q
Tumour Biol; 2016 Sep; 37(9):12791-12803. PubMed ID: 27449032
[TBL] [Abstract][Full Text] [Related]
6. Valproic Acid Induces Endocytosis-Mediated Doxorubicin Internalization and Shows Synergistic Cytotoxic Effects in Hepatocellular Carcinoma Cells.
Saha SK; Yin Y; Kim K; Yang GM; Dayem AA; Choi HY; Cho SG
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28498322
[TBL] [Abstract][Full Text] [Related]
7. Pristimerin synergistically sensitizes conditionally reprogrammed patient derived-primary hepatocellular carcinoma cells to sorafenib through endoplasmic reticulum stress and ROS generation by modulating Akt/FoxO1/p27
Tang Y; Chen J; Li J; Zheng Y; Zhong X; Huang S; Chen B; Peng B; Zou X; Chen X
Phytomedicine; 2021 Jun; 86():153563. PubMed ID: 33951569
[TBL] [Abstract][Full Text] [Related]
8. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
Wang H; Zhang C; Chi H; Meng Z
Int J Oncol; 2018 Jun; 52(6):2051-2060. PubMed ID: 29620259
[TBL] [Abstract][Full Text] [Related]
9. Oridonin synergistically enhances the anti-tumor efficacy of doxorubicin against aggressive breast cancer via pro-apoptotic and anti-angiogenic effects.
Li J; Wu Y; Wang D; Zou L; Fu C; Zhang J; Leung GP
Pharmacol Res; 2019 Aug; 146():104313. PubMed ID: 31202781
[TBL] [Abstract][Full Text] [Related]
10. Strategy to enhance the therapeutic effect of doxorubicin in human hepatocellular carcinoma by selenocystine, a synergistic agent that regulates the ROS-mediated signaling.
Fan C; Zheng W; Fu X; Li X; Wong YS; Chen T
Oncotarget; 2014 May; 5(9):2853-63. PubMed ID: 24797310
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
[TBL] [Abstract][Full Text] [Related]
12. The combination effects of Shen-Ling-Bai-Zhu on promoting apoptosis of transplanted H22 hepatocellular carcinoma in mice receiving chemotherapy.
Xi S; Peng Y; Minuk GY; Shi M; Fu B; Yang J; Li Q; Gong Y; Yue L; Li L; Guo J; Peng Y; Wang Y
J Ethnopharmacol; 2016 Aug; 190():1-12. PubMed ID: 27235019
[TBL] [Abstract][Full Text] [Related]
13. Low‑intensity ultrasound enhances the antitumor effects of doxorubicin on hepatocellular carcinoma cells through the ROS‑miR‑21‑PTEN axis.
Xia C; Zeng H; Zheng Y
Mol Med Rep; 2020 Mar; 21(3):989-998. PubMed ID: 32016465
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial pathway mediated by reactive oxygen species involvement in α-hederin-induced apoptosis in hepatocellular carcinoma cells.
Li J; Wu DD; Zhang JX; Wang J; Ma JJ; Hu X; Dong WG
World J Gastroenterol; 2018 May; 24(17):1901-1910. PubMed ID: 29740205
[TBL] [Abstract][Full Text] [Related]
15. Autophagy inhibition contributes to the synergistic interaction between EGCG and doxorubicin to kill the hepatoma Hep3B cells.
Chen L; Ye HL; Zhang G; Yao WM; Chen XZ; Zhang FC; Liang G
PLoS One; 2014; 9(1):e85771. PubMed ID: 24465696
[TBL] [Abstract][Full Text] [Related]
16. Silencing NOB1 enhances doxorubicin antitumor activity of the papillary thyroid carcinoma in vitro and in vivo.
Liu J; Dong BF; Wang PS; Ren PY; Xue S; Zhang XΝ; Han Z; Chen G
Oncol Rep; 2015 Mar; 33(3):1551-9. PubMed ID: 25592304
[TBL] [Abstract][Full Text] [Related]
17. Beauvericin exerts an anti-tumor effect on hepatocellular carcinoma by inducing PI3K/AKT-mediated apoptosis.
Wang G; Qiao Y; Zhao Y; Song Y; Li M; Jin M; Yang D; Yin J; Li J; Liu W
Arch Biochem Biophys; 2023 Sep; 745():109720. PubMed ID: 37611353
[TBL] [Abstract][Full Text] [Related]
18. Targeted expression of BikDD combined with metronomic doxorubicin induces synergistic antitumor effect through Bax activation in hepatocellular carcinoma.
Dai HY; Chen HY; Lai WC; Hung MC; Li LY
Oncotarget; 2015 Sep; 6(27):23807-19. PubMed ID: 26247632
[TBL] [Abstract][Full Text] [Related]
19. Thymoquinone enhances the anticancer activity of doxorubicin against adult T-cell leukemia in vitro and in vivo through ROS-dependent mechanisms.
Fatfat M; Fakhoury I; Habli Z; Mismar R; Gali-Muhtasib H
Life Sci; 2019 Sep; 232():116628. PubMed ID: 31278946
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of localized ultrasound-targeted microbubble destruction with doxorubicin liposomes in H22 mouse hepatocellular carcinoma model.
Zhu F; Jiang Y; Luo F; Li P
J Drug Target; 2015 May; 23(4):323-34. PubMed ID: 25609362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
